MeiraGTx Holdings plc (MGTX)

4,9900 0,0000 (0,00%) Alla chiusura: 04:00PM EDT

MeiraGTx Holdings plc

450 East 29th Street
14th Floor
New York, NY 10016
United States
646 860 7985
https://meiragtx.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 419

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Alexandria Forbes Ph.D.	CEO, President & Director	2,89M	N/D	1965
Mr. Richard Brian Giroux B.A.	COO & CFO	2,14M	N/D	1973
Dr. Stuart Naylor Ph.D.	Chief Development Officer	1,06M	N/D	1963
Mr. Robert J. Wollin J.D.	General Counsel & Secretary	N/D	N/D	1976
Dr. Michel Michaelides M.D.	Head of Clinical Ophthalmology	N/D	N/D	N/D
Ms. Christine Elise Sheehy	Senior Vice President of Global Integration	N/D	N/D	1968
Mr. Tim Randall	Senior Vice President of Risk & Internal Controls	N/D	N/D	N/D
Dr. Alastair Leighton Ph.D.	Senior Vice President of Manufacturing & Supply Chain	N/D	N/D	N/D
Dr. Robert K. Zeldin M.D.	Chief Medical Officer	1,1M	N/D	1963

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Governance aziendale

L'ISS Governance QualityScore di MeiraGTx Holdings plc al 1 maggio 2024 è 7. I criteri di valutazione fondamentali sono revisione: 4; Consiglio di Amministrazione: 4; diritti degli azionisti: 7; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.